GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect78/100
StatusTERMINATED
PhasePHASE1 / PHASE2
Lead sponsorNovartis Pharmaceuticals
Last update2026-10-21
Public-record facts
| Intervention | JDQ443 (DRUG), trametinib (DRUG), Ribociclib (DRUG), cetuximab (BIOLOGICAL) |
|---|---|
| Condition | KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal |
| Enrollment | 74 |
| Why stopped | Business reasons and not based on any safety concerns. |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is terminated and was updated 2026-10-21.
- It is an interventional PHASE1/PHASE2 study with a named drug/drug/drug/biological intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT05358249. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.